Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Mol Pharm. 2010 Aug 2;7(4):936–943. doi: 10.1021/mp100054m

Figure 4.

Figure 4

2D axial MR images (T1-weighted) of tumor xenografts before (a) and 25 min after (b) the administration of G3-DOTA-Mn, and before (c) and 25 min after (d) the administration of peptide CLT1-targeted G3-Mn. Arrows point tumors.